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Abstract. 
Elevated left atrial (LA) pressures are associated 
with poor prognosis in heart failure (HF). Invasive 
monitoring of LA-pressures and direct mechanical LA-
decompression are associated with functional 
improvement in patients suffering from HF both with 
reduced and preserved ejection fraction. We aim to 
review the current available percutaneously implantable 
sensors for haemodynamic telemonitoring of LA-
pressures (direct LAP sensor device- HeartPOD; right 
ventricular device- Chronicle; pulmonary artery device- 
CardioMEMs). 




Heart failure (HF) is a leading cause of mortality 
and morbidity worldwide. Despite major advances in 
pharmacological and device therapy, hospitalisation  
rates due to cardiovascular causes in patients with HF 
remain high and did not show any significantly 
improvement over the last decades[1, 2]. Indeed, 
preventing acute decompensation in HF patients, both in 
those suffering from HF with reduced (HFrEF) and 
preserved (HFpEF) left ventricular ejection fraction 
(LV-EF) remains challenging. Numerous multivariable 
risk scores have been developed and may help to predict 
mortality, but have shown only a poor discriminative 
ability to predict subsequent cardiac hospitalization in 
patients with HF[3, 4]. Similarly, although a number of 
biomarkers related to cardiomyocyte stress in chronic 
HF have been identified in the last years[5-9], none of 
these have been showed to predict decompensation in 
routine clinical practice[10]. Haemodynamic studies 
have demonstrated that, irrespective of the underlying 
precipitant, the transition from chronic compensated to 
acute decompensated HF is characterized by 
distinguishing and progressive pathophysiological 
alterations[11, 12]. In particular, the increase in left 
atrial (LA) pressure represents the common pathway 
leading to pulmonary congestion and acute pulmonary 
oedema, that account for more than 90% of admissions 
because of acutely decompensated HF[13]. It has been 
shown that a progressive increase in LA pressure is 
apparent weeks before decompensation leading to 
hospital admission. On the contrary, classical symptoms 
and signs like dyspnoea, oedema or weight gain may 
occur only when the decompensation is incipient and 
mostly not avoidable anymore[11]. These 
pathophysiological observations lead to the hypothesis 
that a continuous haemodynamic monitoring of LA 
pressures may be useful to guide therapy of chronic HF 
and prevent acute decompensation. Along the same line, 
recent evidences[14-18] have shown that the 
“decompression” of LA through percutaneous implant 
of unidirectional left-to-right interatrial shunt devices is 
able to ameliorate symptoms in patients suffering from 
HF both with preserved and impaired LV-EF.  
We aimed to review the knowledge regarding 
currently available implantable devices for direct and 
indirect haemodynamic telemonitoring of LA pressures 
in patients with chronic HF. 
 
Implantable device to monitor LA pressures 
LA pressures (LAP) represents the best 
hemodynamic parameter to estimate the left ventricular 
filling pressures. However, in absence of a relevant 
mitral valve stenosis as well as in absence of 
precapillary pulmonary arterial hypertension, the 
pulmonary capillary wedge pressure (PCWP) closely 
correlates with end-diastolic arterial pulmonary pressure 
and can be used in spite of the hardly measurable LAP. 
Similarly, in absence of relevant pulmonary valve 
dysfunction, the right ventricular (RV) pressures closely 
remark the pulmonary artery pressures (PAP)[19]. 
Accordingly, three different devices were developed to 
estimation of left ventricular filling pressures: a direct 
LA pressure sensor, a right ventricular pressure device 
and a pulmonary artery pressure device. 
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Direct left atrial pressure sensor device: 
HeartPOD device 
The HeartPOD device (HeartPOD, Savacor, Inc, 
from St Jude Medical, Inc, Minneapolis, Minn, USA) 
was developed to be implanted in the left atrium and 
direct measure LA pressure, potentially providing more 
accurate assessment of left ventricular filling pressures, 
without potential confounding factors deriving from 
pulmonary vascular abnormalities.  
System and measurement. The HeartPOD left 
atrial sensing device consists of an implantable sensor 
coupled with a subcutaneous antenna coil and a patient 
advisory module (PAM). The sensor system is 
implanted into the atrial septum oriented to the LA and 
is fixed in the interatrial septum through two nitinol 
anchors; it included a 3x7mm sensor module 
hermetically sealed with a titanium pressure sensing 
membrane and circuity to measure LAP, temperature 
and intracardiac electrogram. LAP is obtained by 
subtracting the absolute pressure measured by the 
sensor from the atmospheric one measured by a 
pressure sensor located in the PAM. Measurement and 
calibration are performed through the skin by wireless 
transmissions from the PAM. The acquired waveforms 
are simultaneously stored in the PAM-memory.  
Delivery and implantation. The device is 
implanted through a right heart catheterization (femoral 
or subclavian venous accesses have been described until 
now). Transseptal atrial puncture is performed and an 
11-F sheath is placed in the left atrium. The sensor 
system is advanced under fluoroscopic guidance until 
the distal anchor unfolds and contacts the left side of the 
interatrial septum; then, the sheath is withdrawn to 
release the sensor module. The antenna coil is 
connected to the proximal end of the sensor lead and 
placed in a subcutaneous pocket specifically created 
(usually, in the lower right rectus abdominus sheath in 
case of femoral access or in the pectoral sheath in case 
of subclavian access). After implantation, in patients not 
taking oral anticoagulants, dual antiplatelet therapy with 
acetylsalicylic acid (ASA) and Clopidogrel is 
recommended for a minimum of six months, followed 
by ASA-monotherapy lifetime. Measurement 
acquisitions are made by placing the PAM in proximity 
(< 5 cm) of the subcutaneous pocket. 
Current evidences. The safety and feasibility of the 
HeartPOD device in human settings were evaluated in 
the HOMEOSTASIS (Hemodynamically Guided Home 
Self-Therapy in Severe Heart Failure Patients) trial, a 
prospective, multicentre, observational open-label 
registry enrolling patients with chronic, symptomatic 
HF (HFrEF or HfpEF) and a history of acute 
decompensation. In the pilot HOMEOSTASIS 
study[20], the device was implanted in an initial 
population of 8 patients. After implantation, left atrial 
pressure, temperature and intra-atrial electrogram were 
registered twice daily for 3 months; a clinical 
assessment and a non-invasive device calibration were 
performed at 2, 6 and 12 weeks after implantation. After 
3 months, patients underwent a new right heart 
catheterization, showing a good device accuracy, with 
87% of device LAP measurements being within a 5 
mmHg-deviation from simultaneously invasive 
measurements of pulmonary capillary wedge pressures. 
No device-related complications were observed. The 
safety and the accuracy of this novel interventional 
strategy were confirmed in the long-term report of the 
HOMEOSTASIS study[21], including 84 patients 
undergoing HeartPOD device implantation. No 
intraprocedural complications were observed, nor were 
there any specifically adjudicated to be device related 
during follow-up. The device showed a stable device-
performance over a 4-years follow-up (median time: 14 
months), with a considerable role of the learning curve 
in reducing device failure and measurement artefacts 
(from 12% in the first 43 patients to 0% in the last 41 
patients enrolled), in particular through iterations in 
sensor design and implantation. Whether monitoring of 
LAP through this direct atrial sensor might translate in 
amelioration of symptoms and prognosis of patients 
with chronic HF still need to be investigated. 
 
Devices for indirect estimation of LA pressures. 
Right ventricular pressure sensor- Chronicle 
device 
The first implantable devices aiming to provide an 
invasive hemodynamic monitoring of patients with 
chronic HF were developed in the 1990 and estimated 
left ventricular filling pressures by hemodynamic 
parameters measured in the right ventricle.  
System, implantation and measurement. The right-
ventricular pressure sensor mostly used in the clinical 
research is the Chronicle (Chronicle, Medtronic, 
Minneapolis, Minn, USA) device. It is composed by a 
transvenous lead with a pressure-sensor at the tip and a 
programmable device to process and store information.  
 
Figure 1. Right ventricular device (Chronicle) 
A: Right ventricular implantable device (Chronicle) with the pressure 
sensor at the distal tip of the single right ventricular lead; B: 
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Representative waveforms obtained from the device: 
electrocardiogram, right ventricular (RV) pressure, pulmonary artery 
(PA) pressure and right ventricular dP/dt, ePAD: estimated pulmonary 
artery diastolic pressure; +dP/dtmax: maximum positive dP/dt; -P/dtmax: 
maximum negative dP/dt; PEI:pre-ejection interval; STI: systolic time 
interval. Reproduced with permission of [22] 
It is implanted similar to a single-lead pacemaker, with 
the lead positioned transvenously in the right ventricular 
outflow tract or septum and the device positioned in a 
subcutaneous pocket created in the pectoral area. The 
Chronicle system continuously monitors and stores 
several information including heart fate, body 
temperature, patient activity, right ventricular systolic 
and diastolic pressures, change in right ventricular 
pressure, right ventricular pre-ejection and systolic time 
and estimated pulmonary arterial diastolic pressure 
(ePAD). This latter has been showed to be strongly 
correlated with actual pulmonary artery pressures, 
independently from loading conditions. Chronicle 
device and representative measurement images are 
shown in Figure 1. 
Scientific evidence. A pilot study[22] including 32 
patients with chronic HF in NYHA functional class II 
and III undergoing Chronicle device implantation 
showed that the systolic right ventricular pressure 
considerably increased 4 ± 2 days before occurrence of 
cardiac decompensation leading to hospitalisation. 
Grounded on such physiopathological bases, the 
randomized clinical trial COMPASS-HF (Chronicle 
Offers Management to Patients with Advanced Signs 
and Symptoms of Heart Failure)[23] was conducted on 
277 patients with chronic HF. Patients eligible to 
enrolment should be in NYHA functional class III or IV 
despite ≥ 3 months of optimal medical therapy and have 
experienced at least one episode of cardiac 
decompensation in the previous 6 months. Both HFrEF 
and HFpEF clinical conditions were included.  All the 
study patients underwent Chronicle-implantation and 
were thereafter randomized to treatment group (weekly 
acquisitions of the hemodynamic parameters and 
appropriate therapy-management) or control group (no 
acquisitions of the hemodynamic parameters). 
Implantation was successful in 274 (98.9%) patients. In 
successfully implanted patients, 23 (8.3%) procedure- 
or device-related complications occurred, leading to 
prolonged hospitalisation. However, all complications 
were successfully resolved and resulted in a fully 
functional month follow-up, a not significant reduction 
in HF-related events (including hospitalizations and 
emergency or urgent care visits requiring intravenous 
therapy) was observed in the treatment group (21% 
decrease in event rate versus control group, p=0.33). A 
secondary analysis investigating the time to the first 
hospitalisation because of acutely decompensated HF 
after randomization conversely showed a significantly 
longer event-free survival in patients in the treatment 
group compared with controls (36% reduction in the 
relative risk of HF-hospitalisation, p=0.03). Since the 
event rate in the control group was lower as expected 
(0.85 per 6 patient-months instead that 1.2 per 6 
patients-months), making the study under-powered to 
detect significant differences in clinical events rate, 
studies on larger population are needed to assess 
whether a therapeutic regimen guided by 
haemodynamic monitoring with right ventricular 
implantable device may be helpful in reducing acute 
decompensation in patients with chronic HF. 
 
Pulmonary artery pressure sensor- 
CardioMEMS device 
System and measurement. The CardioMEMS 
Heart Failure Sensor (CardioMEMS Inc., St. Jude 
Medical, Atlanta, Georgia) consists of three 
components: the implantable HF sensor, the delivery 
catheter and an external electronic monitoring unit 
connected with an external antenna. The implantable 
HF sensor is a miniature electrical circuit composed 
from a three-dimensional coil and a pressure-sensitive 
capacitor hermetically sealed and enclosed in a fused 
silica capsule. The device is 15-mm long and 3-mm 
wide and contains two nickel-titanium wire loops 
attached to each end that ensure a stable sensor position 
in the pulmonary artery. Pressure changes in the 
implantable sensor environment result in correlated 
changes to the circuit’s resonant frequency. The coil 
allows for electromagnetic coupling to the sensor by an 
external antenna, which is held against the patient’s 
chest approximately in the area of sensor deployment. 
The antenna provides power to the device and allows 
for continuous measurement of its resonant frequency, 
which is converted in a real-time pressure waveform on 
the electronic monitoring unit. The electronic unit is 
used by the physician to calibrate the HF sensor during 
implant and, after implantation, to take readings of 
hemodynamic data. The haemodynamic data provided 
are the following: PA pressure waveform; systolic, 
diastolic and mean PA pressure; heart rate. These data 
are transmitted to a secure Internet database where they 
are stored and made available for later reading. 
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Figure 2. Pulmonary pressure sensor device (CardioMEMS) 
A: CardioMEMS sensor and delivery catheter and schematic 
representation of the implanted sensor; B: external electronic 
monitoring unit connected with antenna used to calibrate the device 
and to take readings of hemodynamic data; C: representative 
haemodynamic data provided by the device, including pulmonary 
rtery pressure waveforms (systolic, mean and diastolic) and a pressure 
trend graph. Reproduced with permission of [24]. 
Delivery and implantation. The implantable HF 
sensor is connected to a tether wire within a hydrophilic 
delivery catheter and is implanted during a right heart 
catheterization. Femoral venous access is routinely 
used, although a jugular access may be preferred in case 
of severe obesity. After venous cannulation with an 11-
French sheath, a Swan-Ganz catheter is advanced into 
the left or right pulmonary artery tree under 
fluoroscopic guidance and a selective pulmonary 
angiography is performed in order to identify an 
appropriate target artery. Thereafter, a 0.018-inch 
guidewire is placed in the target vessel, the Swan-Ganz 
catheter is retired, and a 12-French sheath is advanced 
over the guidewire, allowing the introduction of the 
CardioMEMS delivery catheter. Once the target site is 
reached, the HF sensor, which is connected to the end of 
the delivery catheter, is released into the target artery. A 
selective angiography is indicated to test the correct 
position of the device and the presence of distal blood 
flow. The delivery system is removed and exchanged 
again with the Swan-Ganz catheter; pulmonary artery 
pressures are acquired through the Swan-Ganz catheter 
and used to calibrate the sensor. Full anticoagulation is 
recommended during the procedure to prevent catheters 
and devices’ thrombosis. Patients not taking oral 
anticoagulants are recommended to undergo dual 
platelet therapy with ASA and Clopidogrel for a month 
after procedure, followed by ASA-monotherapy 
lifelong. Patients on oral anticoagulant therapy are 
recommended to continue their treatment. Device 
components and representative acquired waveforms are 
shown in Figure 2. 
Scientific evidence and current 
recommendations. The CHAMPION (CardioMEMS 
Heart Sensor Allows Monitoring of Pressure to Improve 
Outcomes in NYHA functional Class III Heart Failure 
Patients) study[24] was a prospective, multicentre, 
single-blind randomized clinical trial aiming to 
investigate the impact on of a PA monitoring-guided HF 
therapeutic management on outcome of patients with 
chronic HF. 550 patients with both HFrEF and HFpEF, 
who were in NYHA functional class III despite optimal 
medical therapy and who had at least one hospitalisation 
for decompensated HF within the previous 12 months 
were enrolled. CardioMEMS system for monitoring of 
pulmonary pressures was implanted in the entire study 
population; patients were thereafter randomized to a 
PA-monitoring guided HF therapy or to a control group, 
in which daily uploaded pulmonary pressures were not 
made available. The control group received all standard 
pharmacological and device-based available therapies 
recommended by the currently guidelines. After a mean 
follow-up of 15±7 months, patients randomized to PA 
monitoring-guided therapy showed a 37% reduction in 
HF-related hospitalisation compared with the control 
group (p<0.0001). Such results were confirmed in both 
subgroups of patients with HFrEF[25] and HFpEF[26]. 
The recently published long-term report of the 
CHAMPION trial[27] investigated the impact on 
outcome of “cross-over” of patients formerly in the 
control group to the PA-monitoring-guided group, 
confirming a significant decrease of rates of 
hospitalisation for HF (48%, p<0.0001) when this 
therapeutic strategy was applied compared with 
standard regimen. The CHAMPION trial also 
demonstrated a good safety profile of CardioMEMS, 
with 1 out 550 (0.2%) cases experiencing a failure of 
delivery-system (that required the remotion of the 
system through a snare), no episodes of pulmonary 
infarction or embolism and no events required removal 
of the sensor over the entire follow-up time. According 
with results of the CHAMPION trial, current ESC 
guidelines give a class IIb indication, with level of 
evidence B, for monitoring of PA pressures with 
CardioMEMS in patients with chronic HF who had 
been previously admitted because of decompensation 
and who remain symptomatic despite optimal medical 




Continuous monitoring of LAP through implantable 
devices placed in left atrium, in right ventricle or in the 
pulmonary artery represents a promising strategy to 
dynamically optimize pharmacological therapy and 
prevent acute decompensation in these patients. 
Currently, only pulmonary artery pressure sensor 
(CardioMEMS) has been found to improve symptoms 
and significantly decrease rate of cardiac hospitalization 
and its use may be considered in clinical practice to 
prevent decompensation in symptomatic HF patients. 
On the same pathophysiological basis, the 
interventional creation of a restrictive atrial 
communication to improve symptoms and ameliorate 
loading condition in patients with chronic HF is 
currently under investigation.
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